Calcium, calcium antagonism, atherosclerosis, and ischemia.

Arterial calcinosis, chronic renal failure and calcium antagonism.

Molecular and cellular aspects of calcium channel antagonism.

Ischemia complications after calcium channel blocker poisoning.

Calcium signalling and ER stress in insulin resistance and atherosclerosis.

Radiographically detectable calcium and atherosclerosis: the connection and its exploitation.

The effects of very low external calcium and sodium concentrations on cardiac contractile strength and calcium-sodium antagonism.

Calcium, calcium channels, and calcium channel antagonists.

Effect of ischemia and reperfusion on sarcoplasmic reticulum calcium uptake.

Calcium antagonists and cardiac noradrenaline release in ischemia.

calmodulin dependent protein kinase II after cerebral ischemia.

Calcium binding to fluorescent calcium indicators: calcium green, calcium orange and calcium crimson.

Calcium absorption and calcium bioavailability.

calmodulin-dependent protein kinase activity.

Roles of Calcium Regulating MicroRNAs in Cardiac Ischemia-Reperfusion Injury.

Preliminary clinical experience with calcium antagonists in atherosclerosis. Verapamil in Hypertension Atherosclerosis Study Investigators.

Calcium-activated potassium channels in ischemia reperfusion: a brief update.

The role of calcium ions and calcium channel entry blockers in experimental ischemia-reperfusion-induced liver injury.

Calcium antagonism in essential hypertension: effect on renal haemodynamics and microalbuminuria.

Decreased fibrinolytic activity and increased platelet function in hypertension. Possible influence of calcium antagonism.

Cardiac hypertrophy and aortic compliance after calcium channel antagonism in hypertension.

Calcium and bone health--goodbye, calcium supplements?

Calcium, calcium-antagonistic drugs and the heart.

Smoking, calcium, calcium antagonists, and aging.

Intestinal calcium absorption: calcium entry.

Suggest Documents

Arterial calcinosis, chronic renal failure and calcium antagonism.

Molecular and cellular aspects of calcium channel antagonism.

Ischemia complications after calcium channel blocker poisoning.

Calcium signalling and ER stress in insulin resistance and atherosclerosis.

Radiographically detectable calcium and atherosclerosis: the connection and its exploitation.

The effects of very low external calcium and sodium concentrations on cardiac contractile strength and calcium-sodium antagonism.

Calcium, calcium channels, and calcium channel antagonists.

Effect of ischemia and reperfusion on sarcoplasmic reticulum calcium uptake.

Calcium antagonists and cardiac noradrenaline release in ischemia.

calmodulin dependent protein kinase II after cerebral ischemia.

Calcium binding to fluorescent calcium indicators: calcium green, calcium orange and calcium crimson.

Calcium absorption and calcium bioavailability.

calmodulin-dependent protein kinase activity.

Roles of Calcium Regulating MicroRNAs in Cardiac Ischemia-Reperfusion Injury.

Preliminary clinical experience with calcium antagonists in atherosclerosis. Verapamil in Hypertension Atherosclerosis Study Investigators.

Calcium-activated potassium channels in ischemia reperfusion: a brief update.

The role of calcium ions and calcium channel entry blockers in experimental ischemia-reperfusion-induced liver injury.

Calcium antagonism in essential hypertension: effect on renal haemodynamics and microalbuminuria.

Decreased fibrinolytic activity and increased platelet function in hypertension. Possible influence of calcium antagonism.

Cardiac hypertrophy and aortic compliance after calcium channel antagonism in hypertension.

Calcium and bone health--goodbye, calcium supplements?

Calcium, calcium-antagonistic drugs and the heart.

Smoking, calcium, calcium antagonists, and aging.

Intestinal calcium absorption: calcium entry.

Calcium, calcium antagonism, atherosclerosis, and ischemia.

Recommend Documents

Follow Us